194 related articles for article (PubMed ID: 37204027)
1. Advances in the pharmacotherapeutic management of eosinophilic granulomatosis with polyangiitis.
Pagnoux C; Berti A
Expert Opin Pharmacother; 2023; 24(11):1269-1281. PubMed ID: 37204027
[TBL] [Abstract][Full Text] [Related]
2. Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Pagnoux C; Groh M
Expert Rev Clin Immunol; 2016 Oct; 12(10):1059-67. PubMed ID: 27191665
[TBL] [Abstract][Full Text] [Related]
3. Eosinophilic Granulomatosis With Polyangiitis: Newer Therapies.
Navarro-Mendoza EP; Tobón GJ
Curr Rheumatol Rep; 2018 Apr; 20(5):23. PubMed ID: 29611001
[TBL] [Abstract][Full Text] [Related]
4. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
5. Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.
Tsioulos G; Kounatidis D; Vallianou NG; Koufopoulos N; Katsimbri P; Antoniadou A
Am J Med Sci; 2023 Jan; 365(1):93-98. PubMed ID: 35970248
[TBL] [Abstract][Full Text] [Related]
6. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.
Groh M; Pagnoux C; Baldini C; Bel E; Bottero P; Cottin V; Dalhoff K; Dunogué B; Gross W; Holle J; Humbert M; Jayne D; Jennette JC; Lazor R; Mahr A; Merkel PA; Mouthon L; Sinico RA; Specks U; Vaglio A; Wechsler ME; Cordier JF; Guillevin L
Eur J Intern Med; 2015 Sep; 26(7):545-53. PubMed ID: 25971154
[TBL] [Abstract][Full Text] [Related]
7. Churg-Strauss syndrome.
Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Advances in Eosinophilic Granulomatosis with Polyangiitis.
Bloom JL; Langford CA; Wechsler ME
Rheum Dis Clin North Am; 2023 Aug; 49(3):563-584. PubMed ID: 37331733
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
10. [Eosinophilic granulomatosis with polyangiitis : Update on classification and management].
Hellmich B; Holle J; Moosig F
Z Rheumatol; 2022 May; 81(4):286-299. PubMed ID: 35075511
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
12. Multi-targeted therapy for refractory eosinophilic granulomatosis with polyangiitis characterized by intracerebral hemorrhage and cardiomyopathy: a case-based review.
Mutoh T; Shirai T; Sato H; Fujii H; Ishii T; Harigae H
Rheumatol Int; 2022 Nov; 42(11):2069-2076. PubMed ID: 34287685
[TBL] [Abstract][Full Text] [Related]
13. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
Doubelt I; Pulenzas N; Carette S; Pagnoux C;
Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
[TBL] [Abstract][Full Text] [Related]
15. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
16. A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Quan MV; Frankel SK; Maleki-Fischbach M; Tan LD
BMC Pulm Med; 2018 Nov; 18(1):181. PubMed ID: 30497438
[TBL] [Abstract][Full Text] [Related]
17. Targeting the interleukin-5 pathway in EGPA: evidence, uncertainties and opportunities.
Berti A; Atzeni F; Dagna L; Del Giacco S; Emmi G; Salvarani C; Vaglio A
Ann Rheum Dis; 2023 Feb; 82(2):164-168. PubMed ID: 36357156
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review.
Raffray L; Guillevin L
Drugs; 2018 Jun; 78(8):809-821. PubMed ID: 29766394
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of ANCA-associated vascularitides].
Guillevin L; Pagnoux C
Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
